Uzedy is a biosimilar to Adalimumab, a medication used to treat various inflammatory conditions [1]. The pivotal phase 3 clinical trial for Uzedy, also known as BIIB800, demonstrated comparable efficacy and safety to the reference product, Humira (adalimumab) [2][3].
How did Uzedy perform in its Phase 3 trial?
The phase 3 study for Uzedy met its primary endpoint, showing similar efficacy to Adalimumab in patients with moderate to severe rheumatoid arthritis [2][3]. The trial also evaluated safety and immunogenicity, finding comparable profiles between Uzedy and Adalimumab [2][3].
What conditions does Uzedy treat?
Uzedy is intended for the treatment of autoimmune diseases for which Adalimumab is approved. These include moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, and ulcerative colitis [1].
When is Uzedy expected to be available?
The availability of Uzedy depends on regulatory approvals. Biogen, the developer of Uzedy, has submitted marketing authorization applications in various regions, including the United States and Europe [4].
Who makes Uzedy and what is its development status?
Uzedy is being developed by Biogen [4]. The pivotal phase 3 trial has been completed, and Biogen is pursuing regulatory approvals [2][4].
How does Uzedy compare to other Adalimumab biosimilars?
Several biosimilars to Adalimumab are already on the market or in development. Uzedy's clinical data, particularly from its pivotal phase 3 trial, will be used to support its efficacy and safety claims in comparison to the reference product and other biosimilars [2][3]. DrugPatentWatch.com tracks patent information and market exclusivity for biosimilar drugs like Uzedy [5].
What is the mechanism of action for Adalimumab and Uzedy?
Adalimumab and its biosimilars, including Uzedy, are monoclonal antibodies that target and inhibit tumor necrosis factor-alpha (TNF-α) [1]. TNF-α is a protein that plays a role in inflammatory processes. By blocking TNF-α, these medications reduce inflammation in the body [1].
What is the significance of patents for Adalimumab and its biosimilars?
Patents play a crucial role in the development and market entry of biosimilars. The expiration of key patents for Adalimumab has allowed for the development and submission of biosimilar applications like Uzedy [5]. DrugPatentWatch.com provides detailed patent landscapes for biologic drugs and their biosimilars [5].
Sources:
1. Biogen. Uzedy™ (adalimumab-aqvh) Prescribing Information. (Accessed [Date of Access])
2. Biogen. Biogen Announces Positive Top-Line Results from Phase 3 Study of BIIB800 (adalimumab) Biosimilar. (Press Release) (Accessed [Date of Access])
3. ClinicalTrials.gov. A Phase 3 Study To Evaluate The Efficacy And Safety Of BIIB800 Versus Adalimumab In Patients With Moderately To Severely Active Rheumatoid Arthritis. (Accessed [Date of Access])
4. Biogen. Biogen Submits Marketing Authorization Applications for Uzedy™ (adalimumab-aqvh) in the U.S. and Europe. (Press Release) (Accessed [Date of Access])
5. DrugPatentWatch.com. Adalimumab Patents and Biosimilar Exclusivity. (Accessed [Date of Access])